Cilengitide

Mechanism

A cyclic peptide that was designed to block integrins, the protein "hooks" that help tumors grow new blood vessels and spread. It was tested in a large clinical trial for brain cancer (glioblastoma) but ultimately did not improve survival. Despite the trial failure, it proved the concept of using peptides to target blood vessel growth, and RGD peptides are now widely used as targeting molecules for drug delivery.

Effects

ONCOLOGY/DRUG DELIVERY: Cilengitide is a cyclic RGD pentapeptide (cyclo-RGDfV) that selectively inhibits αvβ3 and αvβ5 integrins — cell surface receptors critical for tumor angiogenesis, invasion, and survival signaling [in vitro, animal]. MECHANISM: The RGD (Arg-Gly-Asp) motif is the minimal recognition sequence for integrin binding to extracellular matrix proteins (fibronectin, vitronectin, fibrinogen). Cilengitide mimics this motif in a cyclic, constrained conformation that provides high-affinity binding to αvβ3 (IC50 ~0.6 nM) and αvβ5 (IC50 ~8 nM) [in vitro]. By blocking these integrins on tumor endothelial cells, cilengitide was designed to inhibit angiogenesis and starve tumors of blood supply. On tumor cells themselves (glioblastoma highly expresses αvβ3), integrin blockade disrupts survival signaling via FAK/Src pathways, inducing detachment-mediated apoptosis (anoikis) [in vitro, animal]. GLIOBLASTOMA RATIONALE: Glioblastoma multiforme (GBM) is highly vascular and expresses abundant αvβ3 integrins — making it a theoretically ideal target. Promising Phase 1/2 data showed median survival of 16.1 months with cilengitide + temozolomide/RT in newly diagnosed GBM (vs. historical 14.6 months) [Phase 2]. However, this did not hold up. CENTRIC TRIAL FAILURE: The Phase 3 CENTRIC trial (Stupp et al., 2014, Lancet Oncology) in MGMT-methylated newly diagnosed GBM showed NO survival benefit — median OS 26.3 months (cilengitide + TMZ/RT) vs. 26.3 months (TMZ/RT alone) in 545 patients. HR 1.02. Complete failure [RCT]. CORE trial in MGMT-unmethylated GBM also negative [Phase 2]. LESSONS LEARNED: Cilengitide's failure taught the field several critical lessons: (1) Anti-angiogenic monotherapy based on a single integrin target is insufficient in GBM. (2) The 'paradoxical dose effect' — at low/intermittent doses, cilengitide may actually promote angiogenesis by transiently activating integrins before blocking them. (3) Drug exposure in the brain may have been insufficient despite good systemic PK. (4) GBM's redundant survival pathways likely compensated for integrin blockade. RGD UTILITY BEYOND CILENGITIDE: Despite cilengitide's clinical failure, the RGD motif remains enormously valuable in drug delivery. RGD-containing peptides are used to target nanoparticles, liposomes, and drug conjugates to αvβ3-expressing tumors and vasculature. Hundreds of RGD-functionalized delivery systems are in preclinical and clinical development [review, ongoing trials].

Practitioner Guide

CLINICAL STATUS: Cilengitide is NOT approved for any indication. Development was terminated after the CENTRIC Phase 3 failure in 2014. It is not available commercially or through clinical trials for glioblastoma. HISTORICAL SIGNIFICANCE FOR PRACTITIONERS: Understanding cilengitide matters for two reasons: (1) It illustrates why promising Phase 2 data must be validated in Phase 3 — the GBM field has many examples of Phase 2 signals that failed to replicate. (2) The RGD targeting concept remains highly relevant in drug delivery and is being applied in next-generation approaches. WHAT WENT WRONG — CLINICAL PERSPECTIVE: The most likely explanation for failure is that αvβ3 integrin inhibition alone is insufficient to control GBM, which has extraordinary molecular heterogeneity and redundant survival mechanisms. Bevacizumab (anti-VEGF, a broader anti-angiogenic approach) also failed to improve OS in GBM (AVAglio, RTOG 0825 trials), suggesting that anti-angiogenic strategies in general have limited efficacy in this disease. Additionally, cilengitide's short half-life (~4 hours) meant intermittent dosing, and preclinical data suggests that sub-inhibitory integrin engagement may paradoxically stimulate angiogenesis. RGD IN CURRENT DRUG DELIVERY: RGD peptides (linear and cyclic) are being used as targeting ligands on: nanoparticles for tumor-targeted chemotherapy delivery, radiolabeled imaging agents (Ga-68/F-18 RGD peptides for integrin PET imaging — in clinical trials), antibody-drug conjugates and peptide-drug conjugates, gene therapy vectors (AAV and lentiviral vectors with RGD modifications for tumor targeting). FOR NEURO-ONCOLOGY PRACTITIONERS: The integrin target itself is not dead — cilengitide was the wrong approach (single-agent, short half-life, possibly wrong dosing schedule). Next-generation integrin-targeted approaches include: bispecific antibodies targeting αvβ3 + another pathway, integrin-targeted radionuclide therapy (similar to Lu-177 DOTATATE concept), and integrin-targeted immunotoxins. CURRENT GBM STANDARD: TMZ + radiation remains standard first-line. TTFields (Optune) added for newly diagnosed. Bevacizumab for recurrence. Immunotherapy trials ongoing. No integrin-targeting therapy in current clinical use.

Evidence

• Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

  Stupp R et al. (2014) — Lancet Oncol — PMID: 25163906

  In 545 patients with newly diagnosed MGMT-methylated glioblastoma, adding cilengitide to temozolomide chemoradiotherapy did not improve overall survival (median 26.3 months in both groups; HR 1.02, 95% CI 0.81-1.29; P=0.86), indicating no survival benefit despite acceptable tolerability.

  strong

Research Summary

TIER 1: CENTRIC Phase 3 RCT (Stupp et al., 2014 — Lancet Oncology): cilengitide + TMZ/RT vs. TMZ/RT in 545 newly diagnosed MGMT-methylated GBM patients. Primary endpoint negative — median OS 26.3 vs. 26.3 months (HR 1.02, p=0.86). PFS also negative (13.5 vs. 10.7 months, HR 0.93, p=0.44). Definitive negative trial. CORE Phase 2 (Nabors et al., 2015): cilengitide in MGMT-unmethylated GBM — also negative. Phase 1/2 (Stupp et al., 2010): cilengitide + TMZ/RT showed 16.1-month median OS, generating the Phase 3 hypothesis. TIER 2: Reviews of integrin biology in cancer (Desgrosellier & Cheresh, 2010). Analysis of cilengitide's failure and lessons for anti-integrin therapy (Mas-Moruno et al., 2016). Reviews of RGD peptides in drug delivery (Danhier et al., 2012 — comprehensive review of RGD-targeted nanoparticles). Preclinical data on paradoxical dose-response effects of integrin inhibitors. TIER 3: Retrospective analyses of cilengitide trial biomarker data. Conference presentations on integrin expression in GBM subtypes. Drug delivery community publications on RGD-functionalized systems. KEY FINDINGS: Cilengitide is oncology's most instructive integrin inhibitor failure. The science was sound (αvβ3 is overexpressed in GBM vasculature), the target was validated, and the Phase 2 data was encouraging — but the Phase 3 was definitively negative. The failure did not invalidate the RGD concept, which thrives in drug delivery and imaging. The lesson: a good targeting peptide does not guarantee a good drug — delivery, dosing, PK, and tumor biology all matter. GAPS: Whether continuous (vs. intermittent) integrin blockade would succeed. Whether combining integrin inhibition with other anti-angiogenic or immunotherapeutic approaches would be effective. Whether cilengitide at different doses or schedules could work. ACTIVE TRIALS: No active cilengitide trials. RGD-based imaging agents (Ga-68/F-18 labeled RGD peptides for αvβ3 PET) in clinical trials for multiple tumor types. RGD-targeted nanoparticles in early-phase clinical trials.